Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics.

ABSTRACT:

Purpose

Type 2 diabetes mellitus (T2DM) with distal symmetric polyneuropathy (DSPN) is a disease involving the nervous system caused by metabolic disorder, while the metabolic spectrum and key metabolites remain poorly defined.

Methods

Plasma samples of 30 healthy controls, 30 T2DM patients, and 60 DSPN patients were subjected to nontargeted metabolomics. Potential biomarkers of DSPN were screened based on univariate and multivariate statistical analyses, ROC curve analysis, and logistic regression. Finally, another 22 patients with T2DM who developed DSPN after follow-up were selected for validation of the new biomarker based on target metabolomics.

Results

Compared with the control group and the T2DM group, 6 metabolites showed differences in the DSPN group (P < 0.0

SUBMITTER: Xu J 

PROVIDER: S-EPMC10105673 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature